Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Branch Retinal Vein Occlusion (BRVO): early-phase trial registry

1 of 1 indexed Branch Retinal Vein Occlusion (BRVO) trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Branch Retinal Vein Occlusion (BRVO): 1 US clinical trial tracked, 1 recruiting.

Branch Retinal Vein Occlusion (BRVO) is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is EyeBiotech, running 1 of these trials.

Enrollment posture brief

Registry condition branch-retinal-vein-occlusion-brvo

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Branch Retinal Vein Occl (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Branch Retinal Vein Occlusion (BRVO)

Branch Retinal Vein Occlusion (BRVO) lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Branch Retinal Vein Occlusion (BRVO) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Branch Retinal Vein Occlusion (BRVO) is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Top Sponsors

EyeBiotech 1 trials

Named interventions

Most-linked intervention names on Branch Retinal Vein Occlusion (BRVO) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Aflibercept 2.0 mg Drug
1 trials
EYE103 Drug
1 trials

US sites by state

Facility locations filed on Branch Retinal Vein Occlusion (BRVO) trials. A trial with sites in several states counts in each.

New Jersey 1 trials
Mississippi 1 trials
Maryland 1 trials
Illinois 1 trials
Florida 1 trials
California 1 trials
Arizona 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Branch Retinal Vein Occlusion (BRVO) page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Branch Retinal Vein Occlusion (BRVO) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • EyeBiotech sponsors the most Branch Retinal Vein Occlusion (BRVO) trials on record, review their full trial history before evaluating a specific study. See EyeBiotech's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Branch Retinal Vein Occlusion (BRVO) condition card totals 1 registered trials; most-linked intervention Aflibercept 2.0 mg; top US site state New Jersey. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.